Drug Search Results
More Filters [+]

PG-116800

Alternative Names: pg-116800, pg116800, pg 116800
Latest Update: 2011-11-04
Latest Update Note: Clinical Trial Update

Product Description

a matrix metalloproteinase inhibitor

Mechanisms of Action: MMP Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Procter and Gamble
Company Location: CINCINNATI OH 45202
Company CEO: Jon R. Moeller
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for PG-116800

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Cardiomegaly|Heart Failure|Myocardial Infarction

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT00067236

P2

Completed

Cardiomegaly|Myocardial Infarction|Heart Failure

2004-12-01

Recent News Events

Date

Type

Title